Articles

A 10-year follow-up of a landmark trial of intensive glucose control in type 2 diabetes has suggested that the clinical benefit was more than durable and rose over time to a reduction or 15% for myocardial infarction and a 13% reduction in the relative risk of death from any cause.

Type 2 diabetes patients treated with a once-weekly version of the incretin mimetic exenatide (Byetta) had better glycemic control than those given the injections twice a day, the standard approach, showed findings published online by The Lancet.

Bristol-Myers Squib and AstraZeneca’s experimental diabetes drug Onglyza significantly improves blood sugar control when added to older medicines, researchers said at EASD.

Type 2 diabetes patients given daily injections of investigational liraglutide atop oral metformin and rosiglitazone (Avandia) achieved significant reductions in plasma glucose by a drop in A1c of 1.5%, with lower blood pressures and weight loss, researchers reported.

In a month-long head-to-head trial, the incretin mimetic exenatide (Byetta) reduced postprandial glucose in type 2 diabetes more than did sitagliptin (Januvia), an oral DPP-4 inhibitor, researchers reported.

Adults with type 1 diabetes achieved significantly better A1c levels with six months of continuous monitoring than with home monitoring, researchers reported.

Adding 50 mg of sitagliptin (Januvia) to pioglitazone (Actos) allowed patients with type 2 diabetes to achieve sustained glycemic control, a yearlong trial showed.

Adolescents and young adults with type 2 diabetes are more likely to have hypertension, generalized obesity, abdominal obesity, low HDL cholesterol, high triglycerides and microalbuminuria, than their non-diabetic counterparts.

New research has shown that XOMA 52, an antibody drug can address the inflammation process which can lead to beta cell death and help to preserve them, plus it is only a once a month dose with little or no side effects.

Results from two Phase 3 Trials, demonstrate the effectiveness of this new rapid –acting insulin